{"id":29383,"date":"2014-08-25T09:48:33","date_gmt":"2014-08-25T13:48:33","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=29383"},"modified":"2014-08-25T09:48:33","modified_gmt":"2014-08-25T13:48:33","slug":"advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383","title":{"rendered":"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &#038; Co., Inc. (NYSE:MRK)"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0<strong>Advaxis, Inc. (NASDAQ:ADXS) <\/strong>announced that it would be taking up testing of experimental <a href=\"http:\/\/finance.yahoo.com\/news\/advaxis-merck-test-immune-therapies-040100227.html\"><strong>immuno-oncology drug<\/strong><\/a>as prostate cancer treatment. Advaxis said that the drug shall be tested along with a much esteemed immunotherapy from <strong>Merck &amp; Co., Inc. (NYSE:MRK)<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Testing the Use of ADXS-PSA<\/strong><\/p>\n<p style=\"text-align: justify;\">Advaxis, Inc. is a small biotechnology company in the States and in the previous month, in second cancer collaboration, it had announced that it was ready to evaluate ADXS-PSA utilization as a sole treatment, while also studying it as a combined treatment with pembrolizumab of Merck in its Phase I and II trials.<\/p>\n<p style=\"text-align: justify;\"><strong>Combination with Merck\u2019s Drug<\/strong><\/p>\n<p style=\"text-align: justify;\">Pembrolizumab is the new drug of Merck &amp; Co., Inc. (NYSE:MRK)\u00a0which belongs to the family of new medicines known as PD-1 inhibitors. This group of medicines function in a way that they block PD-1 protein, thus letting loose the immune system cells, while also pushing them to successfully take on tumours.<\/p>\n<p style=\"text-align: justify;\">The drug by\u00a0Advaxis, Inc. (NASDAQ:ADXS), in turn, is composed of modified form of Listeria bacterium which is impregnated with PSA protein, which in turn is discarded by prostate tumours. This is done so that the immune system activates T-cells (used to kill cancer cells).<\/p>\n<p style=\"text-align: justify;\">The two drug-makers opine that combination of both these drugs will lead to effective knocking of prostate cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>Statement from the Executives<\/strong><\/p>\n<p style=\"text-align: justify;\">In an interview with Yahoo! Finance, the Chief Executive officer of Advaxis, Inc. (NASDAQ:ADXS), Inc., <em>Daniel O&#8217;Connor<\/em> said that the companies will pursue collaboration in case the combination of these two drugs shows positive results. Also, in the interview, O&#8217;Connor said that Advaxis shall be incurring entire cost of study, which is scheduled for early 2015. Merck shall be facilitating pembrolizumab for use in the trial.<\/p>\n<p style=\"text-align: justify;\">On the other hand, <em>David Mauro<\/em>, Executive Director, Merck Oncology Department, said, \u201cWe think this combination gives us the opportunity to do early exploration in prostate cancer and bring immuno-oncology into this space.\u201d<\/p>\n<p style=\"text-align: justify;\">The combination shall also be put on trial in cervical cancer patients, apart from neck and head cancer patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0Advaxis, Inc. (NASDAQ:ADXS) announced that it would be taking up testing of experimental immuno-oncology drugas prostate cancer treatment. Advaxis said that [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":28278,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8342,1683,8343,1123],"stock_ticker":[],"class_list":["post-29383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-advaxis-inc-nasdaqadxs","tag-merck-co-inc-nysemrk","tag-nasdaqadxs","tag-nysemrk","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &amp; Co., Inc. (NYSE:MRK) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &amp; Co., Inc. (NYSE:MRK) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0Advaxis, Inc. (NASDAQ:ADXS) announced that it would be taking up testing of experimental immuno-oncology drugas prostate cancer treatment. Advaxis said that [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-25T13:48:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"275\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &#038; Co., Inc. (NYSE:MRK)\",\"datePublished\":\"2014-08-25T13:48:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\"},\"wordCount\":367,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg\",\"keywords\":[\"Advaxis Inc. (NASDAQ:ADXS)\",\"Merck &amp; Co Inc. (NYSE:MRK)\",\"NASDAQ:ADXS\",\"NYSE:MRK\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\",\"name\":\"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck & Co., Inc. (NYSE:MRK) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg\",\"datePublished\":\"2014-08-25T13:48:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg\",\"width\":275,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &#038; Co., Inc. (NYSE:MRK)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck & Co., Inc. (NYSE:MRK) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383","og_locale":"en_US","og_type":"article","og_title":"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck & Co., Inc. (NYSE:MRK) - Wall Street PR","og_description":"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013\u00a0Advaxis, Inc. (NASDAQ:ADXS) announced that it would be taking up testing of experimental immuno-oncology drugas prostate cancer treatment. Advaxis said that [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-25T13:48:33+00:00","og_image":[{"width":275,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &#038; Co., Inc. (NYSE:MRK)","datePublished":"2014-08-25T13:48:33+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383"},"wordCount":367,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg","keywords":["Advaxis Inc. (NASDAQ:ADXS)","Merck &amp; Co Inc. (NYSE:MRK)","NASDAQ:ADXS","NYSE:MRK"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383","url":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383","name":"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck & Co., Inc. (NYSE:MRK) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg","datePublished":"2014-08-25T13:48:33+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Merck-Co.-Inc..jpg","width":275,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/advaxis-inc-nasdaqadxs-to-start-trial-of-immune-therapies-against-prostate-cancer-in-collaboration-with-merck-co-inc-nysemrk-29383#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Advaxis, Inc. (NASDAQ:ADXS) To Start Trial Of Immune Therapies Against Prostate Cancer In Collaboration With Merck &#038; Co., Inc. (NYSE:MRK)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=29383"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29383\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/28278"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=29383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=29383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=29383"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=29383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}